Journal of Breast Disease

Korean Breast Cancer Society (한국유방암학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer

  • Kim, Sang Hee (Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences) ;
  • Choi, Jihye (Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences) ;
  • Park, Chan Sub (Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences) ;
  • Kim, Hyun-Ah (Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences) ;
  • Noh, Woo Chul (Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences) ;
  • Seong, Min-Ki (Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences)
  • Received : 2018.05.23
  • Accepted : 2018.08.12
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Purpose: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC. Methods: We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy. Results: The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity. Conclusion: Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.

Keywords

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. https://doi.org/10.3322/caac.21262
  2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717. https://doi.org/10.1016/S0140-6736(05)66544-0
  3. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005;104:1742-50. https://doi.org/10.1002/cncr.21359
  4. Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000;26:151-68. https://doi.org/10.1053/ctrv.1999.0161
  5. Osoba D. Health-related quality of life as a treatment endpoint in metastatic breast cancer. Can J Oncol 1995;5 Suppl 1:47-53.
  6. Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 2000;18:2395-405. https://doi.org/10.1200/JCO.2000.18.12.2395
  7. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Trans Med Chir Soc Edinb 1896;15:153-79.
  8. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, et al. Breast cancer version 3.2014. J Natl Compr Canc Netw 2014;12:542-90. https://doi.org/10.6004/jnccn.2014.0058
  9. Dowsett M, Folkerd E, Doody D, Haynes B. The biology of steroid hormones and endocrine treatment of breast cancer. Breast 2005; 14:452-7. https://doi.org/10.1016/j.breast.2005.08.019
  10. Giordano SH, Elias AD, Gradishar WJ. NCCN guidelines updates: breast cancer. J Natl Compr Canc Netw 2018;16(5S):605-10. https://doi.org/10.6004/jnccn.2018.0043
  11. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;371:107-18. https://doi.org/10.1056/NEJMoa1404037
  12. Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90:590-4. https://doi.org/10.1038/sj.bjc.6601557
  13. Cheung KL, Agrawal A, Folkerd E, Dowsett M, Robertson JF, Winterbottom L. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. Eur J Cancer 2010;46:2936-42. https://doi.org/10.1016/j.ejca.2010.08.005
  14. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 2010;28:3917-21. https://doi.org/10.1200/JCO.2009.24.9565
  15. Yao S, Xu B, Li Q, Zhang P, Yuan P, Wang J, et al. Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer. Endocr J 2011;58:509-16. https://doi.org/10.1507/endocrj.K11E-020
  16. Nishimura R, Anan K, Yamamoto Y, Higaki K, Tanaka M, Shibuta K, et al. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. Oncol Rep 2013;29:1707-13. https://doi.org/10.3892/or.2013.2312
  17. Tanaka K, Tokunaga E, Yamashita N, Taketani K, Akiyoshi S, Morita M, et al. Luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer. Surg Today 2014;44:1678-84. https://doi.org/10.1007/s00595-013-0765-4
  18. Park IH, Ro J, Lee KS, Kim EA, Kwon Y, Nam BH, et al. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol 2010;28:2705-11. https://doi.org/10.1200/JCO.2009.26.5884
  19. Michaud LB, Jones KL, Buzdar AU. Combination endocrine therapy in the management of breast cancer. Oncologist 2001;6:538-46. https://doi.org/10.1634/theoncologist.6-6-538
  20. Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park) 2009;23: 133-42.